Mounjaro (Tirzepatide)

Tirzepatide activates both GIP and GLP‑1 receptors, which enhances insulin secretion that depends on glucose, suppresses glucagon release, slows gastric emptying and reduces appetite. These combined actions improve blood sugar regulation and support weight management.

The dose of Mounjaro is individualized by the prescribing healthcare professional. Treatment typically starts at a low dose and is gradually increased based on the patient’s response and tolerability, following the prescriber’s clinical judgment.

Safety of tirzepatide during pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping (including cold‑chain where required) and import documentation.

Mounjaro belongs to the dual GIP/GLP‑1 agonist class, offering broader receptor activation than single‑target GLP‑1 analogues such as semaglutide. Clinical data suggest comparable or greater reductions in HbA1c and body weight, though individual response and safety profiles may differ.

Mounjaro must be stored in a refrigerator at 2‑8 °C. Keep the prefilled pen in its original packaging, protect it from light, and avoid freezing or shaking the product. Do not use if the solution appears discoloured or contains particles.

Mounjaro is given as a subcutaneous injection using a prefilled pen. The injection is administered into the abdomen, thigh or upper arm, rotating sites with each dose. Patients should follow the pen’s instructions and may be taught by a healthcare professional.

Serious risks include pancreatitis, severe allergic reactions such as anaphylaxis, potential thyroid C‑cell tumours (observed in animal studies), and hypoglycaemia when used with insulin or sulfonylureas. Prompt medical attention is required if symptoms of these conditions arise.

Mounjaro is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or a known hypersensitivity to tirzepatide. Caution is also advised for patients with severe gastrointestinal disease or uncontrolled thyroid disorders.